I

InflaRx NV
D

IFRX

0.89220
USD
0.02
(2.75%)
مغلق
حجم التداول
830
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
60,443,989
أصول ذات صلة
A
AMRN
-0.070
(-0.45%)
15.450 USD
C
CRBP
0.18000
(2.00%)
9.17000 USD
M
MTNB
-0.00500
(-0.52%)
0.95000 USD
V
VKTX
0.960
(2.87%)
34.420 USD
المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.